What is the therapeutic effect of inclisiran sodium?

Inclisiran , as a new type of lipid-lowering drug, is gradually becoming an important choice for the treatment of high cholesterol, especially for patients who have poor response to or intolerance to traditional statins. Its main function is to reduce low-density lipoprotein cholesterol (LDL-C) levels by targeting the PCSK9 protein, thereby reducing the risk of cardiovascular disease.

Multiple clinical studies have shown that inkslan sodium has a significant effect in reducingLDL-C levels. In a study involving 3,660 patients, the results showed that after receiving inkslan sodium treatment, the LDL-C levels of the patients were reduced by more than 50%. Most of these patients were also taking statins or other cholesterol-lowering drugs, further supporting the effectiveness of inkslan sodium in combination with these drugs. Particularly in patients who are unable to achieve adequate control on statins, inkslan sodium has shown good supplementation effects.

More importantly, Inkslan sodium is administered less frequently, requiring only a second injection3 months after the initial dose, and then every six months. This convenient dosing method not only improves patient compliance but also makes long-term treatment more feasible. Reducing the frequency of dosing significantly reduces the patient's medication burden compared to taking medications daily or weekly.

In addition, the efficacy of Inkslan sodium is consistent in different groups. Both patients with familial hypercholesterolemia and patients at risk of atherosclerotic cardiovascular disease can achieve significant LDL-C lowering effects. These results provide clinicians with more options when formulating treatment plans, especially when faced with complex cases.

Although the side effects of Inkslan sodium are relatively mild, patients still need to regularly monitorLDL-C levels during use to evaluate the treatment effect and adjust medication. Clinical data show that while Inkslan sodium lowers LDL-C, it does not significantly increase the risk of other cardiovascular events, which provides strong support for its safety.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio